95% CI, 0.51-0.82) lower risk for major adverse cardiovascular events
Approved and investigational indications now span cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis, with one triple-agonist trial even pairing weight loss with relief of knee osteoarthritis pain
A second version of semaglutide called Wegovy, which specifically targets obesity, is also making the rounds and seems to be scarcely available
This could result in more weight loss than older medications that target only a single pathway
Thats why its essential to have a consultation to determine if Ozempic is the right choice for you
Receiving weekly injections of one of these medicines, along with regular weight checks and coaching, has been shown to significantly decrease weight and improve overall health